fair question - if safety data is good (and not sure i have ever read df material risks or adverse effects from refined cbd) then my assumption is that if health claim is fairly lame like sleep benefit then s3 can be granted without p3 trials.
i think if their claim was curing cancer etc they would need p3 trials
but that is not the case
remember the only other TGa; FDA or NHS UK CBD drug was epidiolex for seizures and it did 500m of sales
risk return looks ok 2 me -giddyup
- Forums
- ASX - By Stock
- BOD
- Ann: Quarterly Activities Report and Appendix 4C
Ann: Quarterly Activities Report and Appendix 4C, page-23
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable